Crescent Biopharma, Inc. (CBIO)
Nasdaq · Healthcare · Biotechnology
$13.94−2.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $518M
- 52-week range
- $8.72 – $27.41
- 52-week change
- +26.84%
- EPS (trailing)
- −$7.63
- Analyst rating
- 1.4 Strong buy
Fiscal year to Dec 2025
- Revenue
- $10.8M
- Net income
- $154K
- Operating margin
- −1407.5%
- Free cash flow
- −$72.5M
From the company’s annual report on SEC EDGAR.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 69 employees · crescentbiopharma.com